April 2017 Volume 13, Issue 4
Volume 13, Issue 4 | April 2017
April 2017
In this Issue
Special Reports
Special Report on Neuroscience: Image-ine that
Preclinical in-vivo imaging opens new windows on diseaseDiscovery
A different tack for Alzheimer’s research
‘Jumping genes’ may set stage for brain cell death in Alzheimer’s diseaseAllergens or irritants?
SenzaGen and AstraZeneca collaborate on respiratory technology developmentSanten Inc. tags twoXAR for new deal
Strategic research collaboration will explore new glaucoma treatmentsA pair of GPCR deals for Q1
Heptares inks agreements with Daiichi Sankyo and University of Cambridge centered on GPCRsResearch & Development
‘Eureka moment’
City of Hope researchers identify possible cause of type 1 diabetesIU applies cell coloring technology to battle superbugs
Study sheds new light on the biochemical mechanisms behind cellular division in bacteriaMar matters
Mount Sinai team demonstrates how rare mutations can be lost in stem cell disease modeling of psychosisA new way to study SVs
Posters at AGBT demonstrate clinical significance of next-generation mappingDiagnostics
A clinic-focused agreement
NeoGenomics and Definiens link up for clinical trials, clinical testingGraphene method may lead to low-cost diagnostics
New approach could enable pinpoint diagnostics on individual blood cellsPositive news for ovarian cancer patients
Peregrine shares data supporting a new kind of cancer diagnosticNew answers in search for diabetic kidney disease diagnostics
Mount Sinai team identifies cellular culprits in disease progressionEditor's Focus
That crisp new CRISPR feeling
We peek at some relatively recent CRISPR news to whet your appetite as we get ready to devote a special section to the topic in our May 2017 issueCommentary
Convergence: Where art thou?
There's a lot of talk about the need for convergence in healthcare and life-sciences research, but first we have to cut through a ton of divergent tendenciesGuest Commentary: Using EHR data in research--Pragmatic trials are just the beginning
Pragmatic trials could usher in a new era for discovery, but unless we can consistently apply what we know to patients, such discovery will be for naught; as such, we need to tap into the efficiencies of electronic health records and learn to apply these data and IT systems across the entire spectrum of research activitiesQ&A
Q&A: How electronic data capture is changing clinical trials
Adam Butler of Bracket touches on the growing adoption of eCOA and RTSM in the clinicClinical Trials
Blueprint advances on multiple cancer fronts
Encouraging results seen for both BLU-554 and BLU-285, while BLU-667 gains IND approvalCertara launches Simcyp Access
New licensing approach allows smaller organizations easier access to PBPK modeling and simulation platformREVEAL-ing the truth about CETP inhibitors?
International study examines adding anacetrapib to effective LDL-lowering treatment with atorvastatinSilver lining for selinexor
Karyopharm declares Phase 2 SOPRA study of selinexor a failure, but outlook remains bullishBusiness & Government Policy
Just say yes to druggable targets
New biotech Vividion Therapeutics launches with $50-million Series A financingOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsTargets acquired
A look at a few recent merger and acquisition deals in the pharma worldContract Services
Strengthening standards for clinical research
IAOCR seeks to tighten competency requirements, in part with an eye toward life-sciences health of UK post-BrexitDouble the drug discovery options
Assay.Works and Metrion announce collaboration for expanded service offeringsGenesis Biotechnology acquires PharmOptima
Clients will be able to work with one provider for early discovery through preclinical candidate identificationPreclinical
Making preclinical science stronger
Global Biological Standards Institute’s release of reproducibility report adds rigor to researchJAX vs. TNBC
Defense Department awards Jackson Laboratory major grants to target triple-negative breast cancerValerion reports preclinical potential for Pompe treatment
VAL-1221 could offer more widespread clearance of glycogen than current standard ERTAttune announces ATN-249 preclinical data
Presentation for the oral plasma kallikrein inhibitor for treatment of hereditary angioedema took place at AAAAI 2017Feature
Show Preview: Immunology 2017--In the interests of immunology
The largest annual gathering of immunologists worldwide will hold its annual meeting in Washington, D.C.
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Reliable fluid biomarkers strategies for clinical neuroscience research
Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
Understanding drug impurities: types, sources, and analytical strategies
Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Discovering cutting-edge nitrosamine analysis in pharmaceuticals
New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
